FDA approved a new class of drugs for improving glucose control in adults with T2DM: sodium-glucose co-transporter 2 channel (SGLT-2) inhibitors (SGLT-2i) [94]
In our previous study, galvanized materials were found to efficiently control C
RELATED STORY | Hims and Hers likely to stop selling cheaper versions of GLP-1 medications The drugs have been in short supply since 2022, soon after the FDA approved Wegovy for weight loss purposes
Reproductive outcomes, including ovulation, clinical pregnancy, time to pregnancy, and live birth, were not quantitatively synthesized because their definitions, denominators, and follow-up windows varied substantially across studies and event counts were limited
Prescriptions quadrupled from 2020 to 2022, reaching roughly 9 million , and by 2023 , both Ozempic and Wegovy appeared on the FDA's drug shortage list due to demand exceeding supply